Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy.
Transvascular gene therapy of Parkinson's disease (PD) is a new approach to the gene therapy of PD and involves the global distribution of a therapeutic gene to brain after an intravenous administration and transport across the blood-brain barrier (BBB). This is enabled with the development of a nonviral gene transfer technology that encapsulates plasmid DNA inside pegylated immunoliposomes or PILs. An 85- to 100-nm liposome carries the DNA inside the nanocontainer, and the liposome surface is conjugated with several thousand strands of 2000-Da polyethyleneglycol (PEG). This PEGylation of the liposome stabilizes the structure in the blood stream. The liposome is targeted across the BBB via attachment to the tips of 1-2% of the PEG strands of a receptor-specific monoclonal antibody (mAb) directed at a BBB receptor, such as the insulin receptor or transferrin receptor (TfR). Owing to the expression of the insulin receptor or the TfR on both the BBB and the neuronal plasma membrane, the PIL is able to reach the neuronal nuclear compartment from the circulation. Brain-specific expression is possible with the combined use of the PIL gene transfer technology and brain-specific gene promoters. In the 6-hydroxydopamine rat model of experimental PD, striatal tyrosine hydroxylase (TH) activity is completely normalized after an intravenous administration of TfRmAb-targeted PILs carrying a TH expression plasmid. A treatment for PD may be possible with dual gene therapy that seeks both to replace striatal TH gene expression with TH gene therapy, and to halt or reverse neurodegeneration of the nigro-striatal tract with neurotrophin gene therapy.
Pardridge
William M
WM
Department of Medicine, UCLA, Los Angeles, California 90024, USA. wpardridge@mednet.ucla.edu
D000818:Animals; D001812:Blood-Brain Barrier; D015316:Genetic Therapy; D006801:Humans; D008081:Liposomes; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000235:genetics / Q000628:therapy*; D011092:Polyethylene Glycols; D014446:Tyrosine 3-Monooxygenase / Q000235:genetics / Q000627:therapeutic use*
D008081:Liposomes; D011092:Polyethylene Glycols; D014446:Tyrosine 3-Monooxygenase
Science. 2000 Oct 27;290(5492):767-73
11052933
Pharm Res. 1995 Jun;12(6):807-16
7667183
Neurosci Res. 2001 Sep;41(1):5-12
11535288
Pharm Res. 2001 Aug;18(8):1091-5
11587478
Genesis. 2001 Oct;31(2):85-94
11668683
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12754-9
11592987
Nat Genet. 2002 Feb;30(2):147-8
11799395
J Gene Med. 2002 Mar-Apr;4(2):183-94
11933219
J Biol Chem. 2002 Apr 12;277(15):12649-56
11815603
Nat Rev Drug Discov. 2002 Feb;1(2):131-9
12120094
J Neurosci. 2002 Sep 15;22(18):8034-41
12223557
Cancer Lett. 1996 May 15;103(1):79-84
8616812
J Pharm Sci. 1996 Jun;85(6):612-8
8773958
Nat Med. 1999 Nov;5(11):1256-63
10545991
Pharm Res. 2000 Mar;17(3):266-74
10801214
Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7567-72
10840060
Exp Neurol. 2000 Nov;166(1):1-15
11031079
J Neural Transm Gen Sect. 1995;102(3):175-188
8788067
Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14164-9
8943078
FEBS Lett. 1997 Jan 3;400(2):233-7
9001404
Neuroscience. 1998 Apr;83(4):1225-37
9502260
Neuroreport. 1998 Mar 30;9(5):793-8
9579667
J Neurochem. 1999 Feb;72(2):757-64
9930750
Hum Gene Ther. 1999 Jan 20;10(2):319-32
10022556
Gene Ther. 1998 Dec;5(12):1650-5
10023444
Glia. 1999 Apr;26(2):97-108
10384875
Gene Ther. 1999 Sep;6(9):1574-83
10490767
Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12079-84
10518579
J Chem Neuroanat. 2002 Sep;24(3):173-9
12297263
J Gene Med. 2003 Feb;5(2):157-63
12539153
Hum Gene Ther. 2003 Jan 1;14(1):1-12
12573054
Mol Ther. 2003 Jan;7(1):11-8
12573613
Blood. 2003 Mar 15;101(6):2191-8
12424203
J Comp Neurol. 2003 Jun 23;461(2):250-61
12724841
Eur J Neurosci. 2003 Sep;18(5):1175-88
12956716
Mol Vis. 2003 Oct 3;9:465-72
14551536
Pharm Res. 2003 Nov;20(11):1779-85
14661922
Hum Gene Ther. 2004 Apr;15(4):339-50
15053859
Science. 1981 Nov 20;214(4523):919-21
6117945
Neuron. 1991 Apr;6(4):583-94
1673055
Proc Natl Acad Sci U S A. 1993 May 15;90(10):4698-702
8506321
Glia. 1994 Dec;12(4):281-93
7890332
Synapse. 2001 Feb;39(2):101-8
11180497